Cetrelimab Clinical Trials

5 actively recruiting trials across 4 locations

Also known as: JNJ-63723283

Pipeline

Phase 1: 4Phase 2: 1

Top Sponsors

Johnson & Johnson Enterprise Innovation Inc.2
University Medical Center Groningen1
Janssen Research & Development, LLC1
Ankyra Therapeutics, Inc1

Indications

Cancer5
Lung Cancer2
Metastatic Hormone-sensitive Prostate Cancer1
Metastatic Castration-resistant Prostate Neoplasms1
Locally Advanced Solid Tumor1

Other1 trial

CD8 PET Imaging in Metastatic Solid Tumours

Phase 2

Sarasota, Florida1 trial

A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer

Florida Cancer Specialists

Phase 1

Newnan, Georgia1 trial

A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

City of Hope

Phase 1

Indianapolis, Indiana1 trial

A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

Community Health Network

Phase 1

New York, New York1 trial

A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors

NYU Langone Health

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.